The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Current landscape in the discovery of novel antibacterial agents
Open accessAbstract
BACKGROUND Standard treatments against bacterial infections are becoming ineffective due to the rise of antibacterial resistance worldwide. Classical approaches to develop new antibacterial agents are not sufficient to fulfil the current pipeline, therefore new strategies are currently being devised in the field of antibacterial discovery. OBJECTIVES The objective of this narrative review is to compile the most successful strategies in which research on drug discovery within the antibacterial context is currently ongoing. SOURCES Peer-reviewed publications from the MEDLINE database with robust data addressing the discovery of new antibacterial agents in the current pipeline have been selected. CONTENT Several strategies to discovery new antibacterial are described in this review, such as: i. Derivatives of known antibacterial agents. The activity of a known antimicrobial agent can be improved through two strategies: a) Modification of the original chemical structure of an antimicrobial agent which circumvents antibacterial resistant mechanisms, and b) Development of a compound that inhibits the mechanisms of resistance to an antibacterial agent; ii. New antibacterial agents targeting new proteins; iii. Inhibitors of virulence factors; iv. Nanoparticles; v. Antimicrobial peptides (AMPs) and peptidomimetics; vi. Phage therapy and enzybiotics, and vii. Antisense oligonucleotides. IMPLICATIONS This review intends to provide a positive message affirming that several different strategies to design new antibacterial agents are currently being developed, and we are therefore confident that in the near future some of the most promising approaches will come to fruition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The antimicrobial activity of nanoparticles: present situation and prospects for the future
Wang, L., Hu, C., & Shao, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s121956 · Cited by 4,062
The global threat of antimicrobial resistance: science for intervention.
Roca, I., Akova, M., Baquero, F., Carlet, J., Cavaleri, M., Coenen, S., Cohen, J., Findlay, D., Gyssens, I., Heure, O. E., et al. (2015) · New Microbes and New Infections · doi:10.1016/j.nmni.2015.02.007 · Cited by 1,106
Human commensals producing a novel antibiotic impair pathogen colonization
Zipperer, A., Konnerth, M. C., Laux, C., Berscheid, A., Janek, D., Weidenmaier, C., Burian, M., Schilling, N. A., Slavetinsky, C., Marschal, M., et al. (2016) · Nature · doi:10.1038/nature18634 · Cited by 938
Fleitas Martínez, O., Cardoso, M. H., Ribeiro, S. M., & Franco, O. L. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00074 · Cited by 304
Cited by
Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics
Murugaiyan, J., Kumar, P. A., Rao, G. S., Iskandar, K., Hawser, S., Hays, J. P., Mohsen, Y., Adukkadukkam, S., Awuah, W. A., Jose, R. A. M., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11020200 · Cited by 567
Self-citation
Metadata
- Authors
- Vila, J., Moreno-Morales, J., & Ballesté-Delpierre, C.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 26
- Issue
- 5
- Pages
- 596-603
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W2976543668
- Cited by
- 173
- References
- 4
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current landscape in the discovery of novel antibacterial agents. https://app.cochat.ai/papers/10.1016/j.cmi.2019.09.015
- The paper
- Vila, J., Moreno-Morales, J., & Ballesté-Delpierre, C. (2020). Current landscape in the discovery of novel antibacterial agents. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2019.09.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.